![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 02, 2023 9:15:54 PM
""I was very surprised that the RAS-mutant arm — so, patients that have KRAS, NRAS, or CBL mutations — are just responding beautifully to [lenzilumab], and that really has taken me by surprise,” Thomas said."
But the other reason I added was because Gilead had just the opposite reaction to their trial, using magrolimab. And that opens several doors for lenzilumab. As Durrant said, "These results may create the possibility for lenzilumab development in myelodysplastic leukemias."
I can only imagine the improved morale lenzilumab may bring to cancer health care providers, and patients, where "...treatment options for CMML patients are limited to blood transfusions, hydroxyurea, and supportive care alongside the current standard of care, which includes hypomethylating agents such as azacitidine and decitabine, which have limited response rates of 7% to 18%, with no proven increase in overall survival."
I will be even happier when covid health care providers and patients will also get access to lenz, even if it is for a new variant they haven't seen yet.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM